PGR and breast carcinoma: For breast cancer, levels and extent of oestrogen receptor (ER), progesterone receptor (PR, as a marker of ER function) and HER2 are used to broadly categorize a tumour and inform on the benefit of anti-estrogen agents (e.g., tamoxifen) or tyrosine kinase inhibitors.